$36.19+22.66% · 3M
Moving avg
1W-0.43%
1M+3.71%
3M+23.54%
6M+36.81%
YTD+65.00%
1Y+207.96%
3Y+209.01%
5Y+264.03%
52-week range
$10.9097% of range$37.00
Company health
Value0/6
Growth3/6
Profitability1/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Net cash on the balance sheet
Risks
- Currently unprofitable
- Burning free cash flow
- Revenue shrinking 30% a year
Key statistics
Valuation
Market cap
$26.14B
Enterprise value
$23.67B
P/E ratio (TTM)
-76.87x
P/S ratio (TTM)
3025.18x
EV/EBITDA
-90.62x
Per share & returns
EPS (TTM)
-$0.43
Dividend yield
0.00%
Beta (1Y)
1.11
30-day change
+3.71%
Trading
Volume (24h)
1.52M
Previous close
$36.16
Shares outstanding
722.41M
About Roivant Sciences Ltd.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
ROIV
Roivant Sciences Ltd. is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United Kingdom) and trade under the ticker ROIV.
Frequently asked questions
What is Roivant Sciences Ltd.'s market cap?
Roivant Sciences Ltd. (ROIV) has a market capitalization of $26.14B.
What sector is Roivant Sciences Ltd. in?
Roivant Sciences Ltd. operates in the Healthcare sector, Biotechnology industry.
What exchange does ROIV trade on?
ROIV trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,221.41+0.09%
$1.15T cap
Johnson & JohnsonJNJ
$261.39+0.20%
$629.92B cap
AbbVie Inc.ABBV
$250.64+0.76%
$442.83B cap
UnitedHealth Group IncorporatedUNH
$403.17-0.60%
$366.14B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.62+1.28%
$332.49B cap
Novartis AGSWX: NOVN
CHF 123.96-0.19%
$290.28B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap